Search research articles
Contact Us
Filters
Showing results (291-300 of 785) with videos related to
Page
of 79
Sort By:
Diabetes, Obesity & Metabolism
|
February 11, 2020
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial
Mark E Cooper, Julio Rosenstock, Takashi Kadowaki, et al.
Journal of Hypertension
|
January 14, 2021
Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun
Pantelis Sarafidis, Alberto Ortiz, Charles J Ferro, et al.
Diabetes, Obesity & Metabolism
|
February 15, 2022
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
Sabine Kahl, Anne Pernille Ofstad, Bernard Zinman, et al.
Molecular Genetics & Genomic Medicine
|
February 25, 2022
Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly)
Kolja Lau, Nurcan Üçeyler, Tereza Cairns, et al.
Molecular Genetics and Metabolism
|
May 19, 2023
An expert consensus on the recommendations for the use of biomarkers in Fabry disease
Alessandro Burlina, Eva Brand, Derralynn Hughes, et al.
Circulation. Cardiovascular Genetics
|
January 8, 2014
Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease
Markus Niemann, Arndt Rolfs, Stefan Störk, et al.
Heart (British Cardiac Society)
|
May 12, 2011
Low homoarginine concentration is a novel risk factor for heart disease
Stefan Pilz, Andreas Meinitzer, Andreas Tomaschitz, et al.
European Heart Journal
|
September 11, 2019
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
David Fitchett, Silvio E Inzucchi, Christoph Wanner, et al.
The Lancet. Diabetes & Endocrinology
|
July 2, 2017
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, et al.
Scientific Reports
|
August 27, 2020
Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus
Michael Müller, Carl-Ludwig Schönfeld, Tanja Grammer, et al.
Page
of 79
Search research articles
Search
Showing results (291-300 of 785) with videos related to
Sort By:
Page
of 79
Diabetes, Obesity & Metabolism
|
February 11, 2020
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial
Mark E Cooper, Julio Rosenstock, Takashi Kadowaki, et al.
Journal of Hypertension
|
January 14, 2021
Sodium--glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun
Pantelis Sarafidis, Alberto Ortiz, Charles J Ferro, et al.
Diabetes, Obesity & Metabolism
|
February 15, 2022
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
Sabine Kahl, Anne Pernille Ofstad, Bernard Zinman, et al.
Molecular Genetics & Genomic Medicine
|
February 25, 2022
Gene variants of unknown significance in Fabry disease: Clinical characteristics of c.376A>G (p.Ser126Gly)
Kolja Lau, Nurcan Üçeyler, Tereza Cairns, et al.
Molecular Genetics and Metabolism
|
May 19, 2023
An expert consensus on the recommendations for the use of biomarkers in Fabry disease
Alessandro Burlina, Eva Brand, Derralynn Hughes, et al.
Circulation. Cardiovascular Genetics
|
January 8, 2014
Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease
Markus Niemann, Arndt Rolfs, Stefan Störk, et al.
Heart (British Cardiac Society)
|
May 12, 2011
Low homoarginine concentration is a novel risk factor for heart disease
Stefan Pilz, Andreas Meinitzer, Andreas Tomaschitz, et al.
European Heart Journal
|
September 11, 2019
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
David Fitchett, Silvio E Inzucchi, Christoph Wanner, et al.
The Lancet. Diabetes & Endocrinology
|
July 2, 2017
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, et al.
Scientific Reports
|
August 27, 2020
Risk factors for retinopathy in hemodialysis patients with type 2 diabetes mellitus
Michael Müller, Carl-Ludwig Schönfeld, Tanja Grammer, et al.
Page
of 79